Related Experiment Video
Updated: Jul 7, 2026
06:59
Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
Published on: August 26, 2025
[Antithrombotic therapy after percutanous coronary intervention with stenting]
Harald Vik-Mo1, Morten Slette, Knut Hegbom
1Hjertemedisinsk avdeling, St. Olavs Hospital, 7006 Trondheim. harald.vik-mo@ntnu.no
Summary
Preventing stent thrombosis requires careful management of antiplatelet therapy. Discontinuation of aspirin and clopidogrel, especially before non-cardiac surgery, increases risks. Optimal timing and medication choices are crucial for patient outcomes.
Area of Science:
- Cardiology
- Pharmacology
- Vascular Surgery
Background:
- Stent thrombosis is a serious complication with high mortality.
- Inadequate platelet inhibition is a potential cause of stent thrombosis.
- This review examines long-term antiplatelet treatment effects in patients with coronary stents.
Purpose of the Study:
- To review the management of antiplatelet therapy in patients with coronary stents.
- To identify factors contributing to stent thrombosis.
- To provide guidance on perioperative management and antithrombotic medication.
Main Methods:
- Literature review using Pubmed.
- Analysis of clinical experience.
Main Results:
- Stent thrombosis is linked to premature discontinuation of acetylsalicylic acid and/or clopidogrel.
- Non-cardiac surgery soon after stenting increases stent thrombosis risk.
- Recommendations include delaying non-cardiac surgery (6 weeks for bare metal stents, 6 months for drug-eluting stents) or performing it without drug discontinuation if possible.
- For patients requiring anticoagulation, bare metal stents are preferred, with warfarin, acetylsalicylic acid, and clopidogrel as antithrombotic therapy.
Conclusions:
- Adequate patient, physician, and pharmacy education on antithrombotic drug use is vital.
- Proper medication management can help avoid stent thrombosis and acute myocardial infarction.
Related Concept Videos
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:26Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...